SCHEMBL14978751

SCHEMBL14978751

O=C1N(Cc2ccc(-n3cncn3)cc2)CCN1C1CCNCC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.50
DPP4 P27487 3/20 0.43
DPP8 Q6V1X1 1/20 0.43
CYP11B2 P19099 1/20 0.40
KCNH2 Q12809 1/20 0.39
HCRTR2 O43614 1/20 0.39
KHK P50053 4/20 0.38
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
SMYD3 Q9H7B4 1/20 0.36
RAB9A P51151 1/20 0.36
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
HRH3 Q9Y5N1 1/20 0.35
PRKAB2 O43741 1/20 0.35
PRKAG1 P54619 1/20 0.35
PRKAA2 P54646 1/20 0.35
PRKAA1 Q13131 1/20 0.35
PRKAG3 Q9UGI9 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14978749 0.83 TP53 (0.50) TP53DPP4DPP8KCNH2KHK
SCHEMBL14969478 0.81 TP53 (0.59) TP53DPP4DPP8GPR119
SCHEMBL2855094 0.77 TP53 (0.59) TP53KCNH2KHKALDH1A1CYP2D6
SCHEMBL14968998 0.76 CHRM4 (0.41) DPP4DPP8CYP11B2KCNH2HCRTR2
SCHEMBL3604029 0.74 TP53 (0.58) TP53KCNH2GPR119
SCHEMBL14978757 0.71 TP53 (0.55) TP53KDM4ESMN1; SMN2RAB9A
SCHEMBL14978754 0.70 TP53 (0.51) TP53KHK
SCHEMBL17967842 0.69 DPP4 (0.57) DPP4DPP8CYP11B2KCNH2HCRTR2
SCHEMBL28191629 0.68 DPP4 (0.58) DPP4DPP8CYP11B2KCNH2KDM4E
SCHEMBL16169604 0.66 TP53 (0.51) TP53KHK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140309226-A1 PIPERIDINYL-SUBSTITUTED CYCLIC UREAS AS GPR119 MODULATORS ARRAY BIOPHARMA, INC. 2014-10-16 US disclosed
US-20140309226-A1 PIPERIDINYL-SUBSTITUTED CYCLIC UREAS AS GPR119 MODULATORS ARRAY BIOPHARMA, INC. 2014-10-16 US disclosed
US-20140309226-A1 PIPERIDINYL-SUBSTITUTED CYCLIC UREAS AS GPR119 MODULATORS ARRAY BIOPHARMA, INC. 2014-10-16 US disclosed
WO-2013074641-A1 PIPERIDINYL- SUBSTITUTED CYCLIC UREAS AS GPR119 MODULATORS ARRAY BIOPHARMA INC. (US) 2013-05-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140309226-A1 PIPERIDINYL-SUBSTITUTED CYCLIC UREAS AS GPR119 MODULATORS GPR119, UTS2R, GPR139 TP53 4454/4885DPP4 1179/4885DPP8 1768/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.